Table 2.
Outcome of different grading strategies of each individual pathologist
| P1 | P2 | P3 | Reference Standard* n |
|
| n | n | n | ||
| A. H&E scoring | ||||
| No dysplasia | 26 | 34 | 44 | |
| CIN1 | 31 | 11 | 17 | |
| CIN2 | 16 | 8 | 20 | |
| CIN3 | 20 | 40 | 12 | |
| SCC | 22 | 22 | 22 | |
| B. Ki-67 and p16ink4a immunoscore | ||||
| Immunoscore 0 | 25 | 20 | 0 | |
| Immunoscore 1 | 21 | 10 | 37 | |
| Immunoscore 2 | 4 | 9 | 6 | |
| Immunoscore 3 | 7 | 5 | 5 | |
| Immunoscore 4 | 4 | 3 | 5 | |
| Immunoscore 5 | 9 | 7 | 10 | |
| Immunoscore 6 | 45 | 61 | 52 | |
| C. Combined H&E and non-objectified IHC score | ||||
| No dysplasia | 28 | 35 | 41 | 35 |
| CIN1 | 24 | 12 | 19 | 19 |
| CIN2 | 21 | 8 | 18 | 17 |
| CIN3 | 20 | 38 | 15 | 22 |
| CIN3 | 22 | 22 | 22 | 22 |
*The Reference Standard is defined as the majority diagnosis of the combined H&E and non-objectified IHC score, based on agreement on CIN grade in two out of three pathologists (see also the Methods section).
CIN, cervical intraepithelial neoplasia; IHC, immunohistochemistry; P, pathologist; SCC, squamous cell carcinoma.